Skip to main content
The Society of Thoracic Surgeons

User account menu

  • Log in
Menu

Main navigation

  • FIGHT
    • Coping with Cancer
      • Just Diagnosed
      • In Treatment
      • In Remission
      • Survivorship
    • Cancer Information
      • Bladder Cancer
      • Blood Cancer
      • Breast Cancer
      • Head and Neck Cancer
      • Lung Cancer
      • Melanoma
      • Other
      • Latest Featured Content
      • The Archives
      • Other Resources
    • Find Clinical Trials
    • Glossary
      • Cancer FAQs
  • EDUCATE
    • Current Patient Education Video Series
      • Coronavirus and Covid 19 in the Cancer Community
      • Cancer Information for the Latino Community
      • 2020-21 Patient Education Ambassador's Program
    • GRACE Podcasts
    • Video Library
      • English
      • Spanish
      • Mandarin
  • PARTICIPATE
    • Community Forum
      • Bladder Cancer
      • Blood Cancer
      • Brain Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Gall Bladder and Bile Duct Cancer (Cholangiocarcinoma)
      • Head and Neck Cancer
      • Kidney Cancer
      • Lung Cancer
      • Melanoma
      • Member Updates
      • General Forums
      • Ask A Question
    • Get Involved
      • Memorials and Tributes
      • Volunteer Opportunities
  • ABOUT CancerGRACE
    • GRACE NEWS AND INFO
      • Contact Us
      • How (and Why) to Use GRACE
      • GRACE Public Disclosure Documentation
    • About GRACE
      • Mission
      • Opportunities
      • Terms of Use
      • Our Supporters 2020
    • Our Team
      • Faculty
      • Staff and Board
    • Partnerships
      • GRACE and Clinical Care Options Patient Tools
      • Varian Partner Page 2020
      • Takeda Oncology Partnership Page 2020
      • Lilly Oncology Partner Page
  • DONATE
    • Why Give to GRACE
      • More Ways to Give
      • Corporate Giving Programs
      • Gifts of Stock or Securities
      • Shop and Search for the Cause
      • Create a Tribute
      • Create Your Own Fundraiser
      • Shop with GRACE

Breadcrumb

  1. Home
  2. Forums
  3. Pulsed Tarceva (or other TKIs) and Immunotherapy Drugs - 1289034

Panel Q&A Session on Acquired Resistance with Drs. Riely & Horn

Article

Dr. West moderates a question & answer session with Drs. Leora Horn and Greg Riely on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.

  • Read more about Panel Q&A Session on Acquired Resistance with Drs. Riely & Horn

What is the Role of Immunotherapy for Patients with Advanced NSCLC and a Driver Mutation?

Video

Dr. Greg Riely from Memorial Sloan-Kettering Cancer Center reviews the limited data that help clarify the probability of benefit from new immunotherapy agents among patients with advanced NSCLC and an identified driver mutation.

  • Read more about What is the Role of Immunotherapy for Patients with Advanced NSCLC and a Driver Mutation?

Repeat Biopsies and Emerging Technologies for Plasma Sampling of Mutations Seen with Acquired Resistance

Article

Dr. Leora Horn of Vanderbilt University reviews the rapidly evolving issue and growing value of repeat biopsies, including plasma sampling as a "liquid biopsy" option, in the setting of acquired resistance to a driver mutation in advanced NSCLC.

  • Read more about Repeat Biopsies and Emerging Technologies for Plasma Sampling of Mutations Seen with Acquired Resistance

Panel Q&A Session on Acquired Resistance with Drs. Reckamp & Owonikoko

Article

Dr. West moderates a question & answer session with Drs. Karen Reckamp and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.

  • Read more about Panel Q&A Session on Acquired Resistance with Drs. Reckamp & Owonikoko

Are There Clinically Significant Differences Among the Third Generation EGFR Inhibitors?

Article

Drs. Ben Solomon, Leora Horn, & Jack West compare the clinical data with the third generation EGFR TKIs so active in acquired resistance and consider whether there are significant differences between them.

  • Read more about Are There Clinically Significant Differences Among the Third Generation EGFR Inhibitors?

What is Acquired Resistance to Targeted Therapy, and Why Does it Occur?

Article

Dr. Karen Reckamp of City of Hope Cancer Center reviews the concept of acquired resistance to targeted therapies in patients with a driver mutation and why it occurs.

  • Read more about What is Acquired Resistance to Targeted Therapy, and Why Does it Occur?

The Central Nervous System as a Sanctuary Site: The Special Case for Brain Metastases

Article

Dr. Taofeek Owonikoko reviews why we often see brain metastases develop as a first or only site of progression in patients with NSCLC and a driver mutation.

  • Read more about The Central Nervous System as a Sanctuary Site: The Special Case for Brain Metastases

Does the Specific EGFR Mutation (Including "Rare" Mutations) Matter When Choosing an Oral EGFR Inhibitor?

Article

Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among leading EGFR tyrosine kinases based on the specific EGFR mutation to be treated.

  • Read more about Does the Specific EGFR Mutation (Including "Rare" Mutations) Matter When Choosing an Oral EGFR Inhibitor?

Are There Clinically Significant Differences Among the First and Second Generation EGFR TKIs (Iressa, Tarceva, Gilotrif)?

Article

Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).

  • Read more about Are There Clinically Significant Differences Among the First and Second Generation EGFR TKIs (Iressa, Tarceva, Gilotrif)?

What Are the Treatment Choices for EGFR Mutation-Positive Acquired Resistance in Patients Without a T790M Mutation?

Article

Drs. Ben Solomon, Leora Horn, & Jack West consider the range of treatment options for patients with an EGFR mutation and acquired resistance that does not harbor a T790M mutation.

  • Read more about What Are the Treatment Choices for EGFR Mutation-Positive Acquired Resistance in Patients Without a T790M Mutation?

Pagination

  • Previous page ‹‹
  • Page 2
  • Next page ››
Subscribe to EGFR mutation

Stay In touch

NEWSLETTER SIGN UP

MISSIONDONATEDISCLAIMERRESOURCES

Copyright © 2021 Global Resource for Advancing Cancer Education
Site by Freelock

  • Log in
  • FIGHT
    • Coping with Cancer
      • Just Diagnosed
      • In Treatment
      • In Remission
      • Survivorship
    • Cancer Information
      • Bladder Cancer
      • Blood Cancer
      • Breast Cancer
      • Head and Neck Cancer
      • Lung Cancer
      • Melanoma
      • Other
      • Latest Featured Content
      • The Archives
      • Other Resources
    • Find Clinical Trials
    • Glossary
      • Cancer FAQs
  • EDUCATE
    • Current Patient Education Video Series
      • Coronavirus and Covid 19 in the Cancer Community
      • Cancer Information for the Latino Community
      • 2020-21 Patient Education Ambassador's Program
    • GRACE Podcasts
    • Video Library
      • English
      • Spanish
      • Mandarin
  • PARTICIPATE
    • Community Forum
      • Bladder Cancer
      • Blood Cancer
      • Brain Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Gall Bladder and Bile Duct Cancer (Cholangiocarcinoma)
      • Head and Neck Cancer
      • Kidney Cancer
      • Lung Cancer
      • Melanoma
      • Member Updates
      • General Forums
      • Ask A Question
    • Get Involved
      • Memorials and Tributes
      • Volunteer Opportunities
  • ABOUT CancerGRACE
    • GRACE NEWS AND INFO
      • Contact Us
      • How (and Why) to Use GRACE
      • GRACE Public Disclosure Documentation
    • About GRACE
      • Mission
      • Opportunities
      • Terms of Use
      • Our Supporters 2020
    • Our Team
      • Faculty
      • Staff and Board
    • Partnerships
      • GRACE and Clinical Care Options Patient Tools
      • Varian Partner Page 2020
      • Takeda Oncology Partnership Page 2020
      • Lilly Oncology Partner Page
  • DONATE
    • Why Give to GRACE
      • More Ways to Give
      • Corporate Giving Programs
      • Gifts of Stock or Securities
      • Shop and Search for the Cause
      • Create a Tribute
      • Create Your Own Fundraiser
      • Shop with GRACE